HER-2 and EGFR mRNA expression and its relationship with Versican in malignant matrix-producing tumors of the canine mammary gland

• Autor(a) principal: Karine Araújo Damasceno
• Data de Publicação: 2016
• Outros Autores: Enio Ferreira, Alessandra Estrela da Silva Lima, Conrado de Oliveira Gamba, Fernanda Freitas Miranda, Mariana Rezende Alves, Rafael Malagoli Rocha, André Luís Branco de Barros, Geovanni Dantas Cassali
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFMG
• Texto Completo: https://doi.org/10.1371/journal.pone.0160419; http://hdl.handle.net/1843/39905
• topic: Neoplasias mamárias animais; Versicanas; Receptores de superfície celular; Hibridização in situ; Genes ErbB; Tumor misto maligno; Metástase neoplásica

Versican expression promotes tumor growth by destabilizing focal cell contacts, thus impeding cell adhesion and facilitating cell migration. It not only presents or recruits molecules to the cell surface, but also modulates gene expression levels and coordinates complex signal pathways. Previously, we suggested that the interaction between versican and human epidermal growth factor receptors may be directly associated with tumor aggressiveness. Thus, the expression of EGFR and HER-2 in these neoplasms may contribute to a better understanding of the progression mechanisms in malignant mammary tumors. The purpose of this study was to correlate the gene and protein expressions of EGFR and HER2 by RNA In Situ Hybridization (ISH) and immunohistochemistry (IHC), respectively, and their relationship with the versican expression in carcinomas in mixed tumors and carcinosarcomas of the canine mammary gland. The results revealed that EGFR mRNA expression showed a significant difference between in situ and invasive carcinomatous areas in low and high versican expression groups. Identical results were observed in HER-2 mRNA expression. In immunohistochemistry analysis, neoplasms with low versican expression. showed greater EGFR immunostaining in the in situ areas than in invasive areas, even as the group presenting high versican expression displayed greater EGFR and HER-2 staining in in situ areas. Significant EGFR and HER-2 mRNA and protein expressions in in situ carcinomatous sites relative to invasive areas suggest that these molecules play a role during the early stages of tumor progression.